Something new in the treatment arsenal?
AstraZeneca reported positive results from a Phase 3 trial for a breast- cancer treatment, sending its American depositary receipts higher.
Shares of AstraZeneca (ticker: AZN) were up 1.7% to $68.16 in morning trading.
The company said the trial showed that the treatment, datopotamab deruxtecan, showed a significant improvement relative to chemotherapy in terms of progression-free survival. Plans to submit the drug for regulatory approval globally are underway.
Progression-free survival “is defined as the time from random assignment in a clinical trial to disease progression or death from any cause,” according to the National Library of Medicine.
Interested in more discussions like this? Go to the Breast Cancer Support Group.
Hi @leeann66
So good to hear from you! Sorry to hear about the eye issues, but good to hear they have a treatment plan for that. Anything with eyes is always concerning. It sounds like you are doing great and still enjoying life other than that. Glad the other side effects are improving. Thanks for the great update. You always have such a positive outlook. You’re one of the miracle stories. Prayers that all goes well with your eye procedures. Please let us know how that goes. Enjoy the rest of your summer. Blessings, Zebra